New drug vixarelimab targets gut inflammation in ulcerative colitis trial
NCT ID NCT06693908
First seen Oct 31, 2025 · Last updated May 11, 2026 · Updated 30 times
Summary
This early-stage study tests an experimental drug called vixarelimab in 24 people with moderate to severe ulcerative colitis. The goal is to see how the drug affects inflammation in the gut and how safe it is. Participants must have tried other treatments without success.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Charité Research Organisation GmbH
RECRUITINGBerlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.